Premium
Laboratory and clinical studies of penicillin X‐1497
Author(s) -
Roberts C. Evans,
Allen John D.,
Kirby William M. M.
Publication year - 1961
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt19612170
Subject(s) - penicillin , bacitracin , antibiotics , liter , coagulase , microbiology and biotechnology , staphylococcus , medicine , vancomycin , staphylococcal infections , staphylococcus aureus , bacteria , biology , genetics
Laboratory and clinical studies of a new penicillinase‐resistant penicillin, X‐1497, showed it to be active against coagulase‐positive staphylococci resistant to penicillin G. All fifty strains tested were inhibited by 5 μg per milliliter or less of X‐1497. Staphylococcal killing with X‐1497 was comparable to that with vancomycin and bacitracin. Serum from sub;ects receiving X‐1497 was active against penicillinase‐producing staphylococci. Average peak serum levels were 9.6, 14.6, and 24 μg per milliliter after 0.5, 1.0, and 1.5 Gm. intramuscular injections, respectively. The results of treatment in 23 patients were generally favorable, including 11 cases of staphylococcal infection. The drug was remarkably nontoxic. Although X‐1497 has the disadvantage of requiring frequent intramuscular in;ections to maintain adequate antibiotic blood levels, it promises to be a safe and highly effective antistaphylococcal agent.